Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Istvan Bitter

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
International Review of Psychiatry (Abingdon, England)|September 7, 2012
State of psychiatry in HungaryIstvan Bitter, Tamas Kurimay
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 11, 2025
Negative Symptoms in Schizophrenia: The Placebo Effect as a Barrier to Drug Development?Istvan Bitter, Pal Czobor
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology|April 1, 2011
[Evaluation of the psychometric properties of the Calgary Depression Scale for Schizophrenics (CDSS) in a Hungarian clinical population of patients with schizophrenia]Judit Nagy, Istvan Bitter
Neuro Endocrinology Letters|January 31, 2007
Nonadherence to antipsychotic treatment in patients with schizophrenic disordersJaromir Svestka, Istvan Bitter
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology|September 19, 2012
[Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature]Gabor Gazdag, Judit Tolna, Istvan Bitter
Expert Opinion on Drug Safety|May 7, 2011
Adverse reactions to duloxetine in depressionIstvan Bitter, Dora Filipovits, Pal Czobor
European Psychiatry : the Journal of the Association of European Psychiatrists|August 9, 2005
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO)Istvan Bitter, Pal Czobor, Martin Dossenbach, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 13, 2024
The importance of incorporation of real-world evidence into the guidelines on the pharmacological treatment of schizophreniaIstvan Bitter, Lajos Katona, Peter Falkai, et al.
The British Journal of Psychiatry : the Journal of Mental Science|May 2, 2009
Convulsive therapy turns 75Gabor Gazdag, Istvan Bitter, Gabor S Ungvari, et al.
Schizophrenia Research|October 29, 2005
Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin AmericaSiegfried Kasper, Amanda J Lowry, Andrew Hodge, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
International Review of Psychiatry (Abingdon, England)|September 7, 2012
State of psychiatry in HungaryIstvan Bitter, Tamas Kurimay
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 11, 2025
Negative Symptoms in Schizophrenia: The Placebo Effect as a Barrier to Drug Development?Istvan Bitter, Pal Czobor
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology|April 1, 2011
[Evaluation of the psychometric properties of the Calgary Depression Scale for Schizophrenics (CDSS) in a Hungarian clinical population of patients with schizophrenia]Judit Nagy, Istvan Bitter
Neuro Endocrinology Letters|January 31, 2007
Nonadherence to antipsychotic treatment in patients with schizophrenic disordersJaromir Svestka, Istvan Bitter
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology|September 19, 2012
[Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature]Gabor Gazdag, Judit Tolna, Istvan Bitter
Expert Opinion on Drug Safety|May 7, 2011
Adverse reactions to duloxetine in depressionIstvan Bitter, Dora Filipovits, Pal Czobor
European Psychiatry : the Journal of the Association of European Psychiatrists|August 9, 2005
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO)Istvan Bitter, Pal Czobor, Martin Dossenbach, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 13, 2024
The importance of incorporation of real-world evidence into the guidelines on the pharmacological treatment of schizophreniaIstvan Bitter, Lajos Katona, Peter Falkai, et al.
The British Journal of Psychiatry : the Journal of Mental Science|May 2, 2009
Convulsive therapy turns 75Gabor Gazdag, Istvan Bitter, Gabor S Ungvari, et al.
Schizophrenia Research|October 29, 2005
Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin AmericaSiegfried Kasper, Amanda J Lowry, Andrew Hodge, et al.
Pageof 6